Host biomarkers detected in saliva show promise as markers for the diagnosis of pulmonary tuberculosis disease and monitoring of the response to tuberculosis treatment

Cytokine

Volumn 81, Issue , 2016, Pages 50-56

  Jacobs, Ruschca ^a   Tshehla, Enock ^a   Malherbe, Stephanus ^a   Kriel, Magdalena ^a   Loxton, Andre G ^a   Stanley, Kim ^a   van der Spuy, Gian ^a   Walzl, Gerhard ^a   Chegou, Novel N ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Acute phase proteins; Biomarker; Diagnosis; Saliva; Tuberculosis

Indexed keywords

ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRITIN; FIBRINOGEN; GRANZYME A; HOST BIOMARKER; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM AMYLOID A; SERUM AMYLOID P; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; A2M PROTEIN, HUMAN; CCL2 PROTEIN, HUMAN; CYTOKINE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DRUG MONITORING; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SALIVA ANALYSIS; SALIVA LEVEL; SENSITIVITY AND SPECIFICITY; SYMPTOM; TREATMENT RESPONSE; VALIDATION PROCESS; ANALYSIS OF VARIANCE; CHEMISTRY; DRUG EFFECTS; MIDDLE AGED; PROSPECTIVE STUDY; SALIVA; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

ADULT; ALPHA-MACROGLOBULINS; ANALYSIS OF VARIANCE; ANTITUBERCULAR AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CYTOKINES; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SALIVA; SERUM AMYLOID P-COMPONENT; SOUTH AFRICA; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84957801730     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.02.004     Document Type: Article

References (31)

1. WHO, Global Tuberculosis Report, 2014.
2. Tsara V., Serasli E., Christaki P. Problems in diagnosis and treatment of tuberculosis infection. Hippokratia 2009, 13:20.
3. Uddin M.K.M., Chowdhury M.R., Ahmed S., Rahman M.T., Khatun R., van Leth F., Banu S. Comparison of direct versus concentrated smear microscopy in detection of pulmonary tuberculosis. BMC Res. Notes 2013, 6:291.
4. Zeka A.N., Tasbakan S., Cavusoglu C. Evaluation of the GeneXpert MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in pulmonary and extrapulmonary specimens. J. Clin. Microbiol. 2011, 49:4138-4141.
5. Miotto P., Bigoni S., Migliori G.B., Matteelli A., Cirillo D.M. Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF. Eur. Respir. J. 2012, 39:1269-1271.
6. Marais B.J., Pai M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr. Respir. Rev. 2007, 8:124-133.
7. Sia I.G., Wieland M.L. Current concepts in the management of tuberculosis. Mayo Clin. Proc. 2011, 86:348-361.
8. Munk M.E., Arend S.M., Brock I., Ottenhoff T.H., Andersen P. Use of ESAT-and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis. J. Infect. Dis. 2001, 183:175-176.
9. Sindhu S., Jagannathan N. Saliva: a cutting edge in diagnostic procedures. J. Oral Dis. 2014, 2014:1-8.
10. Schipper R.G., Silletti E., Vingerhoeds M.H. Saliva as research material: biochemical, physicochemical and practical aspects. Arch. Oral Biol. 2007, 52:1114-1135.
11. Phalane K.G., Kriel M., Loxton A.G., Menezes A., Stanley K., van der Spuy G.D., Walzl G., Chegou N.N. Differential expression of host biomarkers in saliva and serum samples from individuals with suspected pulmonary tuberculosis. Mediat. Inflamm. 2013, 2013:1-10.
12. General Discriminant Analysis - Statistics Textbook http://documents.software.dell.com/Statistics/Textbook/General-Discriminant-Analysis.
13. Gruys E., Toussaint M.J.M., Niewold T.A., Koopmans S.J. Acute phase reaction and acute phase proteins. J. Zhejiang Univ. Sci. 2005, 6B:1045-1056.
14. Black S., Kushner I., Samols D. C-reactive protein. J. Biol. Chem. 2004, 279:48487-48490.
15. Shaikh M.K., Samo J.A., Devrajani B.R., Shah S.Z.A., Shaikh S., Shaikh I. C-reactive protein in patients with pulmonary tuberculosis. World Appl. Sci. J. 2012, 17:140-144.
16. Rao S., Bernhardt V. Serum C-reactive protein in pulmonary tuberculosis: correlation with bacteriological load and extent of disease. Infect. Dis. Clin. Pract. 2009, 17:314-316.
17. Du Clos T.W. Pentraxins: structure, function, and role in inflammation. ISRN Inflamm. 2013, 2013:1-22.
18. Noursadeghi M., Bickerstaff M.C., Gallimore J.R., Herbert J., Cohen J., Pepys M.B. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc. Natl. Acad. Sci. 2000, 97:14584-14589.
19. de Haas C.J., van Leeuwen E.M., van Bommel T., Verhoef J., van Kessel K.P., van Strijp J.A. Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation. Infect. Immun. 2000, 68:1753-1759.
20. Kaur S., Singh P.P. Serum amyloid P-component-mediated inhibition of the uptake of mycobacterium tuberculosis by macrophages, in vitro. Scand. J. Immunol. 2004, 59:425-431.
21. Mosesson M.W. Fibrinogen and fibrin structure and functions. J. Thromb. Haemost. 2005, 3:1894-1904.
22. Liu J., Jiang T., Wei L., Yang X., Wang C., Zhang X., Xu D., Chen Z., Yang F., Li J.-C. The discovery and identification of a candidate proteomic biomarker of active tuberculosis. BMC Infect. Dis. 2013, 13:506.
23. Wobeto V.P.de A., Zaccariotto T.R., Sonati M.de F. Polymorphism of human haptoglobin and its clinical importance. Genet. Mol. Biol. 2008, 31:602-620.
24. Ratledge C. Iron, mycobacteria and tuberculosis. Tuberculosis 2004, 84:110-130.
25. Adedapo K.S., Arinola O.G., Ige O.M., Adedapo A.D.A., Salimonu L.S. Combination of reduced levels of serum albumin and αlpha-2-macroglobulin differentiates newly diagnosed pulmonary tuberculosis patients from patients on chemotherapy. Afr. J. Biomed. Res. 2006, 9.
26. Kotru M., Rusia U., Sikka M., Chaturvedi S., Jain A.K. Evaluation of serum ferritin in screening for iron deficiency in tuberculosis. Ann. Hematol. 2004, 83:95-100.
27. Pandey R., Rodriguez G.M. A ferritin mutant of Mycobacterium tuberculosis is highly susceptible to killing by antibiotics and is unable to establish a chronic infection in mice. Infect. Immun. 2012, 80:3650-3659.
28. Opolot J.O., Theron A.J., Anderson R., Feldman C. Acute phase proteins and stress hormone responses in patients with newly diagnosed active pulmonary tuberculosis. Lung 2015, 193:13-18.
29. Visser A., van de Vyver A. Severe hyperferritinemia in Mycobacteria tuberculosis infection. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2011, 52:273-274.
30. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein-(MCP-1): an overview. J. Interferon Cytokine Res. 2009, 29:313-326.
31. Walzl G., Ronacher K., Hanekom W., Scriba T.J., Zumla A. Immunological biomarkers of tuberculosis. Nat. Rev. Immunol. 2011, 11:343-354.